TILT Biotherapeutic Entered into a Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate TILT-123 for Refractory Non-Small Cell Lung Cancer
- The companies collaborated for a P-I dose escalation trial evaluating TILT-123 in combination with Keytruda (pembrolizumab) in 12 to 24 patients with immune checkpoint inhibitor refractory NSCLC
- This recent trial adds to the business' developing data on the utilization of its oncolytic immunotherapy candidate TILT-123, which is presently being tested for multiple other indications and has shown promising results in terms of its usability when administered intravenously
- TILT’s TILT-123 is a 5/3 chimeric serotype adenovirus armed with two human cytokines: TNF alpha and IL-2 where TILT-123 showed a 100% response rate in pre-clinical cancer models in vivo
Ref: Businesswire | Image: TILT Biotherapeutics
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.